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Background: Background : It has been shown that antiproliferative drugs such as
everolimus lower the amount of intimal hyperplasia after stent implantation. We report
a multicenter clinical experience of Xience V/Xience PRIME stent implantation for
in-stent restenosis.
Methods: Methods : From April 2009 to July 2010, 102 consecutives patients (pts)
were enrolled in this trial. However, three patients were excluded at the beginning of
enrolment for major protocol deviation (1 pt with contra-indication to antiplatelet
therapy and 2 pts with incomplete result of other lesions treated before the procedure
of BM in-stent restenosis). Thus 99 pts (16 female, 83 male) with a mean age of 64.4
± 10.2 years were included in this prospective registry. Diabetes mellitus was present
in 24.7 %. The procedure was elective for stable angina or silent ischemia in 70 pts
(70.7 %).
Results: Results : 105 lesions of BM in stent restenosis were treated with a majority
of 1 Xience stent implantation (95 %). 17 pts received 2 stents (1.16 stent per lesion).
One patient died during hospital stay after renal failure and sepsis. Angiographic and
volumetric intravascular ultrasound (IVUS) images were obtained after the procedure
and at 9-month follow-up. Angiographic late loss averaged 0.08 ± 0.54 mm in stent
and 0.12 ± 0.48 mm in segment after 9 months. Neo-intimal volume by 3-dimensional
IVUS (27 pts) was 0.66 ± 0.41 mm3 per mm of length and neo-intimal proliferation
was 8.7 ± 5 % . Initial stent malapposition was observed in two patients, still visible at
9-month follow-up. No proximal or distal edge effect was observed. Six patients had
in-stent restenosis and were treated by another drug-eluting stent in one case and
balloon angioplasty in five cases. There were no death, stent thromboses or any major
adverse cardiac events.
Conclusion: Conclusion : This study demonstrates the safety and the potential utility
of everolimus-eluting Xience V/Xience prime stent for the treatment of BM in-stent
restenosis.
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Background: Drug-eluting balloons (DEB) are a good treatment for in-stent restenosis
(ISR), with angiographic advantages (by quantitative coronary angiography [QCA])
and clinical benefits. However, little is known about the morphological and functional
values of this treatment option, as measured by Fractional flow reserve (FFR) and
optical coherence tomography (OCT). We aimed at quantifying these parameters in
patients with ISR treated with DEB, and relating them to QCA parameters.
Methods: In this ongoing prospective observational study, 20 patients with culprit ISR
lesions in native coronary arteries underwent serial FFR and OCT assessment at
baseline, after intervention with DEB and at 6-month follow-up. FFR is assessed in
the distal part of the target vessel (“real FFR”), then distal and proximal of the stent
margins (generating an in-stent FFR gradient as difference between the 2 values).
Results: At baseline results were: reference vessel diameter 2.29±0.52 mm, minimal
luminal diameter (MLD) 0.64±0.35 mm, percent diameter stenosis (%DS) 72±14%
(QCA), “real FFR” 0.58±0.18, in-stent FFR gradient 0.35±0.18 (FFR), lumen volume
110±46, MLD 1.21±0.30, and minimal luminal area (MLA)1.48±0.62 (OCT). Post-
procedural results: MLD 2.09±0.38 mm, %DS 13±9% (QCA), “real FFR” 0.88±0.08,
in-stent gradient 0.06±0.05 (FFR), lumen volume 171±64, MLD 2.16±0.38, and MLA
4.64±1.51 (OCT). Follow-up results: MLD 1.90±0.67 mm, %DS 24±19%, late loss
0.21±0.61 mm (QCA), “real FFR” 0.86±0.12, in-stent gradient 0.04±0.05 (FFR), lumen
volume 180±57, MLD 2.11±0.34, and MLA 4.50±1.60 (OCT).
Results
Conclusion: Drug-eluting balloon treatment of ISR confirms its previous effectiveness,
with maintenance at mid-term follow up of the post-procedural, functional and
morphological results.
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Background: The success of percutaneous intervention in peripheral arterial disease
is limited by restenosis. Aim of this study was evaluation of efficacy and safety of a
novel paclitaxel-coated balloon catheter for reduction of restenosis after PTA of
femoropopliteal arteries.
Methods: Design: two treatment arms, randomized enrollment of 91 patients. Inclusion
criteria: clinical Rutherford stage 1-5, occlusion or hemodynamic relevant stenosis (≥
70 % diameter) of femoropopliteal arteries, successful guide wire passage. Treatment
of 1-3 lesions/patient each with 1-5 uncoated (Pacific Xtreme™) or paclitaxel-coated
(In.Pact Pacific™) balloon catheters strictly controlled in respect of paclitaxel content
before and after use. Primary endpoint: late lumen loss at 6 months follow-up evaluated
by an independent blinded core lab. Clinical follow-up at 6, 12, and 24 months,
respectively.
Results: Inclusion period ended in February 2011. Overall 91 patients were included;
mean age, 70 years; maximum lesion length up to 30 cm; 27 % occlusions; 23 %
restenosis or in stent restenosis. All patients have been successfully treated. Twenty
seven percent of the study lesions were stented. Up to now no coating-related adverse
events were observed. Moreover, early promising results have been seen in a proportion
of patients upon first follow-up visits.
Conclusion: This is one of few controlled randomized trials with drug-coated balloons
in peripheral arteries. So far, paclitaxel-coated balloon catheter angioplasty in
femoropopliteal lesions has been shown to be a safe procedure. Exact numbers and
efficacy results at 6 month angiography follow-up will be available at the meeting in
November 2011.
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Background: Coronary bifurcations are frequently encountered in contemporary
interventional practice. Clinical outcomes are in general inferior in bifurcation lesions
compared to non-bifurcation lesions. We investigated safety and performance of
Nobori, a new generation DES for this lesion subset. The platform with a large open-
cell design for easy side branch access coated only abluminally with a biodegradable
polymer and Biolimus A9 may have an optimal design for treatment of bifurcation
lesion.
Methods: Among 3067 consecutive patients enrolled in 125 centers worldwide in the
NOBORI2 registry, 695 patients had at least one bifurcation lesion treated. Primary
endpoint of the study was target lesion failure (TLF) defined as cardiac death, target
vessel related MI and target lesion revascularization (TLR) at 1 year. Data were entered
in an electronic database and 100% monitored on-line; events are adjudicated by
independent experts and data are analysed by an independent corelab.
Results: Lesions in the bifurcation group were significantly more complex, more
frequently located in the LAD, LM and at the ostium with a higher degree of
eccentricity. The majority of the lesions were classified as 1.1.0. (37.6%), 1.1.1 (26.2%)
and 0.1.0 (9.3%) with 190 true bifurcation lesions (27%). At 2 years, TLF rate was
5.9% in the bifurcation and 4.8% in the non-bifurcation group (p=NS). Cardiac death
was 0.7% vs 1.9% (p<0.03), target vessel related MI 2.3% vs 1.3% (p=NS) and TLR
4.0% vs 2.7% (p=NS). The rate of stent thrombosis was similar in both groups (0.7%
in bifurcation and 0.9% in non-bifurcation group; p=NS).
Conclusion: Low rates of TLF and stent thrombosis at two years indicate that Nobori
DES is safe and effective for the treatment of bifurcation lesions. The large cell opening
of this stent with enhanced access to side branch, the biodegradable polymer and the
abluminal coating might have contributed to good outcome.
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